CJC-1295 Without DAC
Also Known As: CJC-1295 no DAC, Mod GRF 1-29, Modified GRF 1-29, Modified GRF, ModGRF, CJC1295 without DAC, Sermorelin analog, GHRH 1-29 analog, Growth hormone releasing hormone 1-29, CJC 1295 no-DAC, Short-acting GHRH analog, Modified growth releasing factor, GRF 1-29 tetrasubstituted, MOD GRF 1-29, GHRH, growth hormone releasing hormone, CJC 1295, CJC no DAC
CJC-1295 Without DAC is a research-grade Short-acting synthetic GHRH analog targeting GHRH receptor studied in Muscle Growth & Performance research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A short-acting growth-hormone-releasing peptide, usually paired with a GHRP; banned in sport.
At A Glance
| Category | Muscle Growth & Performance |
|---|---|
| Compound Class | Short-acting synthetic GHRH analog (Mod GRF 1-29); no albumin-binding DAC moiety |
| Molecular Target | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; augments natural pulsatile GH release |
| Molecular Weight | 3357.9 Da |
| Amino Acid Sequence | tetrasubstituted GRF(1-29) amide |
| CAS Number | 863288-34-0 |
| Half-Life | ~30 min (pulsatile) |
| WADA Status | prohibited |
| Evidence Tier | Research Compound |
Mechanism Of Action
It perfectly mimics your natural growth hormone-releasing hormone. It connects to the pituitary gland to trigger a fast, natural spike in growth hormone, then breaks down completely within about 30 minutes.
Studied For
- Pulsatile GH simulation
- GH secretagogue research
- Sleep quality improvement
- Stacked with ipamorelin for synergistic GH release
- Anti-aging via GH axis
- Body composition / lean mass
- GH deficiency models
- Fat loss via GH axis
- Recovery and tissue repair via GH
- Bone density support
- IGF-1 elevation
- Collagen synthesis promotion
- Skin quality research
- Athletic performance research
- GH pulse amplitude enhancement
- muscle growth
- fat loss
- deep sleep
- anti-aging
- vitality
- collagen production
- recovery
Reported Research Findings
Mechanistic plausibility rests on native GHRH physiology and on GHRH-plus-GHRP synergy. Controlled trials of this specific analog are sparse; preliminary.
Safety And Handling Notes
Injection-site reactions, flushing, headache, lightheadedness, mild water retention; short half-life limits exposure.
Not approved; growth-hormone-axis risks apply. WADA-prohibited. Frequently mislabeled simply as CJC-1295 without the DAC distinction. Research use only.
Regulatory Status
Not FDA-approved; research chemical; WADA S2.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.